VALN
Valneva SE NASDAQ Listed May 5, 2021$5.19
-0.38%
vs $5.21
Mkt Cap $436.4M
52w Low $5.17
0.3% of range
52w High $12.20
50d MA $5.61
200d MA $8.40
P/E (TTM)
-3.2x
EV/EBITDA
—
P/B
4.1x
Debt/Equity
1.9x
ROE
—
P/FCF
-7.6x
RSI (14)
29.60
ATR (14)
$0.16
Beta
1.53
50d MA
$5.61
200d MA
$8.40
Avg Volume
30.2K
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
6 rue Alain Bombard · Saint-Herblain, I0 44800 · FR
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -0.17 | -0.68 | -293.1% | 10.51 | +2.0% | +4.8% | +1.6% | -6.2% | -1.7% | -37.1% | — |
| Nov 20, 2025 | AMC | -0.30 | -0.61 | -103.3% | 8.53 | +2.1% | +1.1% | +2.3% | -0.9% | +9.2% | -1.9% | — |
| Aug 12, 2025 | AMC | -0.27 | -0.16 | +40.7% | 9.40 | +11.2% | +18.7% | -6.2% | +10.1% | +5.3% | -5.6% | — |
| May 7, 2025 | AMC | -0.31 | -0.13 | +58.1% | 6.59 | -4.9% | -3.2% | +1.4% | -0.3% | -1.1% | +0.5% | — |
| Mar 20, 2025 | AMC | -0.22 | -0.54 | -145.5% | 7.25 | +0.7% | -1.1% | +3.6% | -4.8% | +1.3% | +1.3% | — |
| Nov 7, 2024 | AMC | -0.30 | -0.15 | +50.0% | 5.48 | -2.7% | -4.4% | -2.1% | -6.6% | +3.5% | -0.2% | — |
| Aug 13, 2024 | AMC | -0.39 | -0.37 | +5.1% | 7.45 | +4.0% | +4.6% | -2.3% | -1.2% | +13.8% | -1.6% | — |
| May 7, 2024 | AMC | 0.77 | 0.89 | +15.6% | 7.50 | -3.2% | -3.5% | -1.7% | +4.2% | +2.6% | +5.3% | — |
| Mar 20, 2024 | AMC | 0.20 | -0.50 | -350.0% | 7.10 | +6.1% | +4.4% | +3.8% | +1.6% | +0.1% | +1.8% | — |
| Nov 9, 2023 | AMC | -0.51 | -0.54 | -5.9% | 13.75 | +5.4% | +0.5% | -0.7% | -3.7% | -3.9% | +0.5% | — |
| Sep 21, 2023 | AMC | -0.36 | -0.26 | +27.8% | 13.01 | -2.7% | -1.8% | -0.6% | -5.0% | -3.7% | -2.2% | — |
| May 4, 2023 | AMC | -0.35 | -0.28 | +20.0% | 11.58 | +7.7% | +11.2% | -4.9% | +0.1% | -1.2% | +3.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Goldman Sachs | Downgrade | Neutral → Sell | $5 | $5.93 | $5.61 | -5.4% | -11.5% | +1.5% | +3.2% | -0.2% | +0.7% |
| Sep 8 | Guggenheim | Maintains | Buy → Buy | — | $8.65 | $8.46 | -2.2% | -1.5% | +4.8% | +1.5% | +1.3% | -2.6% |
| Aug 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.64 | $9.12 | -21.6% | -19.0% | -5.0% | -2.3% | +1.0% | +0.1% |
| May 8 | Guggenheim | Maintains | Buy → Buy | — | $6.59 | $6.27 | -4.9% | -3.2% | +1.4% | -0.3% | -1.1% | +0.5% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.05 | $7.18 | +1.8% | +0.0% | -6.8% | +3.3% | -2.4% | +2.7% |
| Apr 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.04 | $6.12 | +1.3% | +12.1% | -6.8% | -0.3% | +12.1% | +0.0% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.76 | $6.88 | +1.8% | +2.4% | +0.7% | -14.2% | +4.3% | -3.2% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.26 | $6.80 | -6.3% | -7.6% | +0.7% | +2.4% | +0.7% | -14.2% |
| Mar 24 | Guggenheim | Maintains | Buy → Buy | — | $7.17 | $7.62 | +6.3% | +3.6% | -4.8% | +1.3% | +1.3% | +0.1% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.17 | $7.62 | +6.3% | +3.6% | -4.8% | +1.3% | +1.3% | +0.1% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.25 | $7.30 | +0.7% | -1.1% | +3.6% | -4.8% | +1.3% | +1.3% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.12 | $7.03 | -1.3% | -5.2% | +1.0% | +0.3% | +4.4% | -3.9% |
| Feb 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.33 | $7.58 | +3.4% | +2.9% | +4.9% | -5.9% | +5.0% | -5.1% |
| Feb 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.61 | $6.21 | +10.7% | +18.9% | +3.9% | -6.6% | +8.2% | +11.9% |
| Jan 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.25 | $5.78 | +10.1% | +10.1% | -7.1% | +4.5% | +18.9% | +3.9% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.63 | $4.89 | +5.6% | +2.4% | +3.4% | -1.0% | +2.1% | +2.4% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.71 | $4.68 | -0.6% | -1.7% | +2.4% | +3.4% | -1.0% | +2.1% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.69 | $5.63 | -1.1% | -1.1% | +0.4% | -1.8% | +0.9% | +0.4% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.98 | $6.09 | +1.8% | +0.8% | +1.3% | +1.6% | -2.7% | -4.5% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.32 | $7.32 | +0.0% | -0.7% | -1.0% | -1.8% | -1.0% | -1.1% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.45 | $7.75 | +4.0% | +4.6% | -2.3% | -1.2% | +13.8% | -1.6% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.05 | $7.01 | -0.6% | +0.3% | -3.3% | +2.3% | -2.1% | +0.0% |
| Jul 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.46 | $7.70 | +3.2% | +1.5% | -3.6% | -1.8% | +1.3% | -0.1% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.13 | $7.01 | -1.7% | -1.7% | +1.4% | +2.0% | -0.8% | -1.9% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.18 | $7.48 | +4.2% | +8.9% | -4.5% | -1.3% | -3.3% | -1.7% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.08 | $9.16 | +0.9% | -2.8% | -3.1% | -2.1% | +0.0% | -5.1% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.90 | $8.94 | +0.4% | +1.9% | +0.1% | -2.8% | -3.1% | -2.1% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.73 | $8.95 | +2.5% | -1.4% | -1.0% | +1.5% | +2.8% | +0.1% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.42 | $7.45 | +0.4% | +2.6% | +5.3% | +10.5% | -0.3% | +0.7% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.50 | $7.26 | -3.2% | -3.5% | -1.7% | +4.2% | +2.6% | +5.3% |
| Mar 22 | Guggenheim | Maintains | Buy → Buy | — | $7.41 | $7.54 | +1.8% | +3.8% | +1.6% | +0.1% | +1.8% | -0.5% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.10 | $7.53 | +6.1% | +4.4% | +3.8% | +1.6% | +0.1% | +1.8% |
| Feb 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.30 | $6.99 | -4.2% | -2.7% | -0.4% | -3.8% | -1.9% | -0.4% |
| Feb 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.03 | $8.39 | +4.5% | +3.7% | -4.2% | -9.5% | +0.4% | -0.6% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.50 | $11.08 | -3.7% | -0.2% | +0.2% | -3.9% | +2.2% | -1.2% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.75 | $14.49 | +5.4% | +0.5% | -0.7% | -3.7% | -3.9% | +0.5% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.06 | $11.89 | -1.4% | -3.7% | -2.2% | +1.9% | -2.1% | -1.7% |
| Sep 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.69 | $13.42 | -1.9% | +1.1% | -0.9% | +1.2% | -2.2% | -0.4% |
| Aug 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.81 | $13.91 | +0.7% | +0.7% | +1.1% | -0.5% | -0.3% | -0.4% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.50 | $14.00 | +3.7% | +2.3% | +0.7% | +1.1% | -0.5% | -0.3% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.27 | $13.65 | -4.3% | -2.3% | -5.2% | -1.7% | +1.0% | +0.0% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.55 | $11.93 | +3.3% | +1.4% | -2.6% | +9.4% | +1.8% | -0.6% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.58 | $12.47 | +7.7% | +11.2% | -4.9% | +0.1% | -1.2% | +3.6% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.63 | $19.45 | -0.9% | -2.6% | -1.0% | +1.4% | -0.3% | -5.8% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 12
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 85,962 | $758K | Added | Dec 2025 |
| 2 | Wells Fargo & Company/mn | 78,029 | $488K | New | Mar 2026 |
| 3 | Hrt Financial Lp | 20,847 | $130K | New | Mar 2026 |
| 4 | Vsm Wealth Advisory, Llc | 10,000 | $62K | New | Mar 2026 |
| 5 | China Universal Asset Management Co., Ltd. | 5,000 | $44K | New | Dec 2025 |
| 6 | Gamma Investing Llc | 1,426 | $9K | Reduced | Mar 2026 |
| 7 | Eversource Wealth Advisors, Llc | 121 | $7K | Reduced | Mar 2026 |
| 8 | Ubs Group Ag | 782 | $5K | Added | Mar 2026 |
| 9 | Bnp Paribas Financial Markets | 200 | $1K | New | Mar 2026 |
| 10 | Clearstead Advisors, Llc | 48 | $303 | — | Mar 2026 |
| 11 | Smartleaf Asset Management Llc | 43 | $266 | — | Mar 2026 |
| 12 | Activest Wealth Management | 1 | $9 | — | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | General American Investors Company, Inc. | 354,361 | $2M | Mar 2026 |
| 2 | Fidelity Nasdaq Composite Index Fund | 2,880 | $32K | Feb 2026 |
Valuation
Market Cap
$436.4M
Enterprise Value
$488.0M
P/E (TTM)
-3.18x
Forward P/E
—
PEG Ratio
-0.01x
P/B
4.11x
P/S
2.79x
P/FCF
-7.61x
EV/EBITDA
—
Shares Out
84.1M
Financials (TTM)
Revenue
$156.3M
Net Income
-$138.0M
EBITDA
-$90.1M
Free Cash Flow
-$57.4M
Op Cash Flow
-$52.9M
EPS Basic
$-1.32
EPS Diluted
$-1.63
EPS Forward
$-0.82
Gross Margin
29.5%
Op Margin
-63.6%
Net Margin
-88.3%
Balance Sheet
Total Assets
$398.8M
Total Liab.
$292.7M
Total Equity
$106.2M
Cash
$109.7M
LT Debt
$161.3M
Book Value/Sh
$1.26
Debt/Equity
1.95x
Current Ratio
2.38
Quick Ratio
1.85
Returns & Growth
ROE
—
ROA
—
ROIC
-25.0%
Rev Growth YoY
+3.0%
EPS Growth YoY
-656.9%
Price Returns
2W
+5.2%
1M
+16.2%
3M
-43.6%
6M
-33.2%
12M
-2.3%
Technicals
52W High
$12.20
52W Low
$5.17
50d MA
$5.61
200d MA
$8.40
RSI (14)
29.60
ATR (14)
$0.16
Beta
1.53
Avg Volume
30K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$11.00
High
$11.00
Low
$11.00
Median
$11.00
Data updated apr 24, 2026 11:17am
· Source: financialmodelingprep.com